Onco Wiki / Regimen

Sofosbuvir/Velpatasvir 12 weeks

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-SOFOSBUVIR-VELPATASVIR
IDREG-DAA-SOF-VEL
TypeRegimen
Statusreviewed 2026-04-24 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-EASL-HCV-2023 SRC-ESMO-MZL-2024 SRC-MOZ-UA-LYMPH-2013

Notes

First-line antiviral regimen for HCV-associated lymphoproliferative disease. Achieves SVR12 (cure) in >95% of treatment-naive non- cirrhotic patients. Lymphoma regression often follows viral clearance in 4-12 months; formal reassessment at 6 months.

Used By

Access Pathways

Algorithms

Indication